Imbruvica (Ibrutinib) induced subcutaneous hematoma: A case report
Chronic Lymphocytic Leukemia (CLL) is one of the lymphoid neoplasms mainly affecting adults over age 55. Ibrutinib (Imbruvica) is currently the first-line therapy for various stages of CLL. It inhibits Bruton's Tyrosine Kinase (BTK). The most common adverse drug reactions include diarrhea, nausea, f...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2021-03-01
|
| シリーズ: | Current Problems in Cancer: Case Reports |
| 主題: | |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2666621921000168 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|